Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Forte Biosciences, Inc.

Forte Biosciences Announces Pricing of $75 Million Public Offering
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences Announces Proposed Public Offering
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences to Host R&D Day December 3, 2024
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.